Buy 5-Fluoro-αMT Cas 712-08-3

Buy 5-Fluoro-αMT Cas 712-08-3

5-Fluoro-αMT, also known as 5-fluoro-α-methyltryptamine (5F-AMT) or by its developmental code names PAL-212^[2][3] and PAL-544,^[4][5] is a monoaminergic drug of the tryptamine and α-alkyltryptamine families related to α-methyltryptamine (αMT).^[2][3][4] It is taken orally.^[1][6]

The drug is known to act as a serotonin receptor agonist,^[2][3] monoamine releasing agent,^[2][3][4] and potent monoamine oxidase inhibitor.^[7][8] It produces psychedelic– and stimulant-like effects in animals.^{[9][8][10][11]} 5-Fluoro-AMT is also known to be psychoactive in humans, though its effects have not been well-described.^[1][6]

5-Fluoro-AMT was first described in the scientific literature by 1963.^[11] There has been interest in 5-fluoro-AMT as a possible treatment for cocaine dependence.^[4]

5-Fluoro-AMT has been said to be psychoactive in humans at a dose of 25 mg orally, although the qualitative nature of these effects has not been well-described.^[1][6] Preclinical studies suggest that 5-fluoro-αMT may be a psychedelic, stimulant, and/or entactogen in humans.^{[2][3][4][9][8][10][11]} However, 5-fluoro-AMT may be dangerous in humans due to its concomitant potent monoamine oxidase inhibition.^[7][12]

William Leonard Pickard has described his experiences with 5-fluoro-AMT, which he had synthesized along with 6-fluoro-AMT, in personal interviews.^[6] According to Pickard, 5-fluoro-AMT had a duration of at minimum 9 hours and varied in length significantly.^[6] The dose was 25 mg and above.^[6] Pickard has said that 5-fluoro-AMT was not a “warm drug” but that he remained favorable to it.^[6] Its effects included time dilation among others.^[6] He said that it gave him the worst post-trip headaches he’d experienced from any psychedelic and they lasted up to 24 hours.^[6]

Pickard has said that 5-fluoro-AMT is less potent and long-lasting than 6-fluoro-AMT.^[6] The related drug AMT was one of Pickard’s favorite psychedelics, and he said that he took it more than 50 times and experienced no negative side effects with it.^[6]

5-Fluoro-AMT has been found to act as a fairly balanced serotonin-norepinephrine-dopamine releasing agent (SNDRA),^[4][2] as a serotonin 5-HT_2A receptor agonist,^[2][13] and as a potent and specific MAO-A inhibitor.^{[12][14][15][16][17]} Its EC₅₀Tooltip half-maximal effective concentration values in terms of monoamine release are 14 to 19 nM for serotonin, 78 to 126 nM for norepinephrine, and 32 to 37 nM for dopamine in rat brain synaptosomes.^[4][2][3] The drug’s EC₅₀ at the serotonin 5-HT_2A receptor is 8.47 nM and its E_maxTooltip maximal efficacy at the receptor is 107%.^[3] The IC₅₀Tooltip half-maximal inhibitory concentration of 5-fluoro-AMT for MAO-A is 180 to 450 nM.^[7][8][12] This is similar to the potency of αMT, para-methoxyamphetamine (PMA), and 4-methylthioamphetamine (4-MTA).^[7]

5-Fluoro-αMT induces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.^[9][8][10] It is also known to reverse reserpine-induced behavioral depression, suggesting that it has antidepressant– or stimulant-like effects as well.^[11] 5-Fluoro-AMT does not substitute for cocaine in drug discrimination tests but did substitute for cocaine in monkeys.^[4] It does not facilitate intracranial self-stimulation (ICSS) in rodents.^[4]

Analogues of 5-fluoro-AMT include 5-fluorotryptamine, 5-fluoro-DMT, 5-fluoro-AET, and BK-5F-NM-AMT, as well as 5-chloro-αMT, 6-fluoro-AMT, 7-chloro-AMT, 7-methyl-αET, 5-API (PAL-571), and flucindole, among others.

BK-5F-NM-AMT, the N–methyl and β-keto derivative of 5-fluoro-AMT, is a serotonin–dopamine releasing agent (SDRA) analogously to 5-fluoro-AMT.^[18] In contrast to 5-fluoro-AMT and many other tryptamines however, BK-5F-NM-AMT is inactive as an agonist of serotonin receptors including the 5-HT₁, 5-HT₂, and 5-HT₃ receptors and is inactive as a monoamine oxidase inhibitor (MAOI).^[18]

5-Fluoro-AMT was first described in the scientific literature, by Asher Kalir and Stephen Szara, by 1963, and was described as showing antidepressant– or stimulant-like effects in rodents.^[11] It was first tried in humans by 1984.^[1] The drug’s psychedelic-like effects in animals were described by 1995.^[10] 5-Fluoro-AMT’s monoamine release and serotonin receptor agonism were shown by 2014, along with support for it having stimulant-like effects in monkeys.^[2][3][4] The drug was investigated as a possible candidate for treatment of cocaine dependence and these findings were published in 2014.^[4]

5-Fluoro-AMT is not an explicitly nor implicitly controlled substance in Canada as of 2025.^[19]

5-Fluoro-AMT is not an explicitly controlled substance in the United States.^[20] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.